Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
The Zoetis Foundation announced its first round of 2023 grants totaling $5.3 million, supporting 21 initiatives across 15 countries, benefiting livestock farmers and veterinary professionals, and providing earthquake relief in Türkiye. The funding aims to enhance veterinary education, promote diversity, and improve mental well-being in the profession. Notably, the Foundation has committed an additional $100,000 to the American Red Cross for Türkiye earthquake aid. Zoetis Inc. plans to distribute a total of $35 million in grants by the end of 2025, focusing on community and profession support.
Zoetis Inc. (NYSE: ZTS) is set to host a webcast and conference call on May 4, 2023, at 8:30 a.m. (ET) to discuss its first quarter 2023 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from financial analysts. Interested investors and the public can access the live webcast through the Zoetis website, and a replay will be available following the event. In 2022, Zoetis generated impressive revenue of $8.1 billion and continues to lead in animal health innovation across over 100 countries.
Summary not available.